




Newly Reported Substances: The following substances were reported to NFLIS-Drug for the first time between **October 1, 2021, and December 31, 2021.**




South

1cP-LSD




Midwest


Bromo-DMT



Homoamphetamine




Trifluoromethyl U-47700




Northeast


BZO-POXIZID



5F-BZO-POXIZID



BZO-HEXOXIZID




Snapshot of Drug Reports Received by NFLIS-Drug


The tables on the right present the top five drug reports in each category received by NFLIS-Drug between October 1, 2021, and December 31, 2021.

Narcotic Analgesics	11,166	Benzodiazepines	7,815	Synthetic Cathinones	2,244
Buprenorphine	2,997	Alprazolam	3,545	Eutylone	1,908
Oxycodone	2,790	Clonazolam	1,273	Dipentylone	62
Tramadol	2,642	Clonazepam	1,026	alpha-PiHP	61
Hydrocodone	1,386	Etizolam	774	BMDP	41
Morphine	317	Flualprazolam	378	alpha-PHP	31
Cannabinoids	39,080	Synthetic Cannabinoids	2,441		
Cannabis/THC	36,549	ADB-BUTINACA	917		
Tetrahydrocannabinol/tetrahydrocannabinolic acid	983	MDMB-4en-PINACA	886		
Cannabidiol	759	Fluoro-MDMB-PICA ¹	139		
delta-8-Tetrahydrocannabinol	438	Fluoro-MDMB-BUTINACA ¹	87		
Cannabinol	135	Fluoro-EMB-PICA ¹	45		


Upward Trends, by Date Submitted to Laboratory



Xylazine



delta-10-Tetrahydrocannabinol



Fluorofentanyl¹

¹ Includes all positional and nonspecified isomers as reported by participating laboratories.

Data Disclaimer: Substances identified by Federal, State, and local laboratories are included in the raw counts of drug reports received by NFLIS-Drug. Raw counts have not undergone any adjustments to account for laboratory nonresponse. Data for this publication were exported from the NFLIS-Drug database in January 2022. Data in the Newly Reported Substances and Snapshot of Drug Reports Received by NFLIS-Drug sections include only drugs submitted to laboratories on or after October 1, 2020. Because of the time it takes for a laboratory to analyze seized material and transfer the data to the NFLIS database, the data in this publication—unlike those reported in an Annual or Midyear Report—are not comprehensive and do not reflect total counts of drugs analyzed over the period. More information on NFLIS data limitations can be found in the NFLIS Questions and Answers guide: <https://www.nflis.deadiversion.usdoj.gov/nflisdata/docs/2k17NFLISQA.pdf>. NFLIS reports are available at <https://www.nflis.deadiversion.usdoj.gov/publicationsRedesign.xhtml>. Questions and comments: NFLIS@dea.gov

